Synapse loss in Alzheimer's disease (AD) correlates with cognitive decline. Involvement of microglia and complement in AD has been attributed to neuroinflammation, prominent late in disease. Here we show in mouse models that complement and microglia mediate synaptic loss early in AD. C1q, the initiating protein of the classical complement cascade, is increased and associated with synapses before overt plaque deposition. Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss. C1q is necessary for the toxic effects of soluble b-amyloid (Ab) oligomers on synapses and hippocampal long-term potentiation. Finally, microglia in adult brains engulf synaptic material in a CR3-dependent process when exposed to soluble Ab oligomers. Together, these findings suggest that the complement-dependent pathway and microglia that prune excess synapses in development are inappropriately activated and mediate synapse loss in AD.
G
enome-wide association studies implicate microglia and complement-related pathways in Alzheimer's disease (AD) (1) . Previous research has demonstrated both beneficial and detrimental roles of complement and microglia in plaque-related neuropathology (2, 3); however, their roles in synapse loss, a major pathological correlate of cognitive decline in AD (4), remain to be identified. Emerging research implicates microglia and immunerelated mechanisms in brain wiring in the healthy brain (1) . During development, C1q and C3 localize to synapses and mediate synapse elimination by phagocytic microglia (5-7). We hypothesized that this normal developmental synaptic pruning pathway is activated early in the AD brain and mediates synapse loss.
The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles, and neuronal loss (8, 9) . To determine how early synapse loss occurs, we used superresolution structured illumination microscopy (SIM) (10) to quantify synapse density in hippocampal CA1 stratum radiatum of familial AD-mutant human amyloid precursor protein (hAPP) ("J20") transgenic mice (11) . Quantification of colocalized pre-and postsynaptic puncta [synaptophysin and postsynaptic density 95 (PSD95) (Fig. 1A) ; synaptotagmin and homer ( fig. S1 , A to D)] revealed a significant loss of synapses in J20 hippocampus at 3 to 4 months old (mo), an age that precedes plaque deposition (11, 12) . Synapse loss in preplaque J20 CA1 was confirmed by electron microscopy ( fig. S1G ). Confocal imaging also showed synapse loss in CA1, CA3, and dentate gyrus of 3 mo J20 hippocampus but not in striatum ( fig. S1E ). Synapse levels were not altered in 1 mo J20 brains versus wild-type (WT) littermates ( fig. S1F ), suggesting that the hippocampal synaptic loss at 3 mo is likely not a result of abnormal synaptic development.
We asked whether the classical complement cascade is up-regulated in preplaque brains when synapses are already vulnerable. C1q immunoreactivity (13) (antibody now available at Abcam) was elevated in J20 brains as early as 1 mo and preceding synapse loss (Fig. 1B and fig. S1 ). C1q elevation was region-specific, particularly in the hippocampus and frontal cortex, two regions vulnerable to synapse loss (14) (Fig. 1B and fig.  S2A ). C1q immunoreactivity was comparable between J20 and WT mice at postnatal day 21 (P21) ( fig. S2B ), suggesting that elevated levels at 1 mo are likely not a developmental artifact. C1q was also similarly increased in the hippocampus of another model of AD, the APP/PS1 (presenilin 1) mice (15) (fig. S2C) . Notably, SIM demonstrated colocalization of C1q with PSD95-positive puncta in 1 mo J20 hippocampus (Fig. 1C) . A higher percentage of PSD95 colocalized with C1q in the hippocampus of J20 mice than in that of WT littermates (Fig. 1D and fig. S3 ), suggesting that the C1q-associated synapses may be marked for elimination.
Punctate Ab was found deposited in J20 hippocampus at 1 mo ( fig. S4 ), long before Ab plaques deposit (11, 12) , raising the question of whether C1q increase in these preplaque brains is dependent on soluble Ab levels. To test this hypothesis, we injected the mice with compound E, a g-secretase inhibitor that rapidly decreases Ab production (12) . Compound E markedly reduced soluble Ab levels in J20 mice; there was a corresponding reduction of C1q deposition (Fig. 1E) , suggesting that Ab up-regulates C1q. Compound E reduces deposited soluble Ab (red) and C1q (green) in 1 mo J20 dentate gyrus, with minimal effect on C1q levels in WT mice. Scale bar, 2 mm (A, C, and D) or 10 mm (B and E). Means ± SEM; n = 3 or 4 mice per genotype or per treatment group per genotype. *P < 0.05, **P < 0.01, or ***P < 0.001 using two-way analysis of variance (ANOVA) followed by Bonferroni posttest (A and B), two-tailed one-sample t test (D), or twotailed unpaired t test (E).
sciencemag.org SCIENCE . Means ± SEM; n = 3 to 5 mice per treatment group per genotype. *P < 0.05 using two-tailed t test (B) or *P < 0.05, **P < 0.01 versus control-treated or ## P < 0.01 versus Ab monomer-treated using two-way ANOVA followed by Bonferroni posttest (C). (E and F) Genetic deletion of C3 prevents synapse loss in 4 mo APP/ PS1 mice. Quantification of colocalized immunoreactive puncta for synaptotagmin and homer in dentate gyrus (E) or synaptophysin and PSD95 in CA1 stratum radiatum (F) of WT, APP/PS1, APP/ PS1xC3 KO, and C3 KO hippocampi. Means ± SEM; n = 3 to 5 mice per genotype or per treatment group per genotype. *P < 0.05, **P < 0.01, or ***P < 0.001 using two-tailed one-sample t test (D), oneway (A, C, E, F) or two-way (B) ANOVA followed by Bonferroni posttest. ns, not significant.
To further address whether the increase of C1q is dependent on soluble Ab, and if so, which species, we injected soluble Ab oligomers or monomers into lateral ventricles of WT mice. Hippocampus contralateral to the injection site was examined to avoid any surgery-related effects. Oligomeric Ab (oAb), which is prefibrillar in nature and acts as a mediator of synapse loss and dysfunction in AD (4), but not the relatively innocuous monomeric Ab or vehicle, induced C1q deposition ( Fig. 2A and fig. S5 ). A higher percentage of PSD95 colocalized with C1q in oAb-injected versus monomer-injected mice (Fig.  2B) , in a manner similar to this colocalization in J20 mice. Together, these findings show an early and aberrant increase and synaptic localization of C1q in multiple AD model systems. Furthermore, fluorescent in situ hybridization (FISH) demonstrated up-regulated C1qa expression in microglia ( fig. S6) , implicating microglia as a major source of C1q in these preplaque brains.
To test whether C1q and oAb act in a common pathway to eliminate synapses, we injected oAb into lateral ventricles of C1qa knockout (KO) mice (16) . Soluble oAb induced a significant loss of colocalized synapsin-and PSD95-immunoreactive puncta in WT mice within 72 hours (Fig. 3A , left panel) (17) . In contrast, oAb failed to induce synapse loss in C1qa KO mice (Fig. 3A, right panel) , suggesting that C1q is required for oAb-induced synapse loss in vivo. To determine whether local, acute inhibition of C1 activation could similarly blunt the synaptotoxic effects of oAb, we used an antibody against C1q (anti-C1q) (ANX-M1, Annexon Biosciences), which blocks the classical complement cascade (see fig. S7 and supplementary methods). Coadministration of the ANX-M1 anti-C1q antibody, but not its immunoglobulin G (IgG) isotype control, prevented oAb from inducing synapse loss in WT mice (Fig. 3B) . Thus, blocking C1 activation by either genetic or antibodymediated means lessened oAb's synaptotoxic effects.
To determine whether C1q is associated with synaptic dysfunction, we asked whether the established ability of oAb to potently inhibit long-term potentiation (LTP) (4) was dependent on C1q. We tested the functional effects of the ANX-M1 anti-C1q antibody in acute hippocampal slices treated with oAb. IgG alone had negligible effects on LTP induction in WT mouse hippocampal slices and on the ability of oAb to inhibit LTP; however, pretreatment of hippocampal slices with the anti-C1q antibody significantly prevented the impairment of LTP by oAb (Fig. 3C) . Neither ANX-M1 nor its IgG control altered basal synaptic neurotransmission ( fig. S8) . Collectively, these results in hippocampal slices and in mice support C1q as a key mediator of oAb-induced synaptic loss and dysfunction.
In the healthy developing brain, C1q promotes activation of C3, which opsonizes subsets of synapses for elimination, a process that is downregulated in the mature brain (5, 6). However, oAb induced a significant C3 deposition in WT adult mice ( fig. S7A, upper panel) . This was significantly reduced in both the C1qa KO ( fig. S7A , lower panel) and the ANX-M1 anti-C1q antibodytreated WT mice ( fig. S7B) , suggesting that the C3 deposition in this model is downstream of the classical complement cascade. Consistent with these findings, a higher percentage of PSD95 colocalized with C3 in J20 and APP/PS1 brains ( Fig. 3D and fig. S9 ). To determine whether C3 is necessary for early synapse loss in AD genetic models, we crossed APP/PS1 mice, which, similar to the J20 mice, had a significant increase and localization of C1q and C3 onto hippocampal synapses (figs. S2C and S9), to C3-deficient mice (18) . Quantification of colocalized pre-and postsynaptic puncta demonstrated synapse loss in 4 mo APP/PS1 hippocampus as compared to WT; however, APP/PS1xC3 KO mice did not display this synapse loss (Fig. 3, E and F) . Together, our data indicate that genetic deletion of C3 ameliorates synapse loss in APP/PS1 mice, providing further evidence that the classical complement cascade mediates early synapse loss in AD mouse models.
Microglia express complement receptors and mediate synaptic pruning in the developing brain (1, 6) , raising the question of whether this normal developmental pruning pathway could be activated to mediate synapse loss in the preplaque AD brain. Consistent with this hypothesis, microglia had increased amounts of the lysosomal protein CD68 in J20 hippocampus compared to WT and less so in striatum, a less vulnerable region (figs. S1C and S10). Furthermore, in WT mice challenged with oAb, microglia had significantly increased levels of CD68 immunoreactivity (Fig. 2C) . However, in C1qa KO mice in which synapse loss was rescued, oAb failed to induce such an increase (Fig. 2D) , suggesting that microglia eliminate synapses through the complement pathway.
To directly test whether phagocytic microglia engulf synaptic elements, we adapted our in vivo synaptic engulfment assay (19) using intracerebroventricular injections of Ab in homer-GFP (green fluorescent protein) mice (20) (Fig.  4A) . oAb induced a significantly higher volume of internalized homer-GFP in microglia than monomeric Ab controls did at the contralateral hippocampus (Fig. 4B) , indicating that microglia engulf synaptic elements when challenged with oAb. Internalized homer-GFP often colocalized (A and B) . Means ± SEM; n = 3 mice per treatment group per genotype (n = 6 to 17 microglia analyzed per mouse). *P < 0.05, **P < 0.01, or ***P < 0.0001 using two-tailed t test (B) or two-tailed one-sample t test (C and D). ns, not significant.
with CD68 ( fig. S11A) , suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to that of developmental synaptic pruning (6) . Notably, oAb failed to increase synaptic engulfment in microglia lacking CR3 (21), a high-affinity receptor for C3 expressed on macrophages [homer-GFPxCR3 KO versus homer-GFP mice, which received tail vein injections of phosphatebuffered saline (PBS) or oAb (Fig. 4C) ]. These data demonstrate that CR3 is necessary for oAb-dependent engulfment of synapses by microglia.
To test whether inhibition in microglial engulfment leads to protection against oAb-induced synapse loss, we performed tail vein injections of oAb into WT and CR3 KO mice. oAb induced synapse loss in the hippocampus of WT mice but not in that of CR3 KO mice (Fig. 4D) . All CR3-positive microglia were P2RY12-positive ( fig. S11 ), indicating that they are resident cells (22) . Altogether, these results suggest that resident microglia engulf synaptic material when challenged by oAb through a complement-dependent mechanism.
Synaptic deficits occur in early AD and mild cognitive impairment before onset of plaques and are some of the first signs of the neuronal degenerative process (4, (23) (24) (25) . Here we identify critical synaptotoxic roles of complement and microglia in AD models before plaque formation and neuroinflammation, in regions of the hippocampus undergoing synapse loss. Using multiple experimental approaches, we demonstrate a region-specific increase of phagocytic microglia and accumulation of C1q and C3 on synapses in preplaque brains. Microglia in the adult brain, when challenged with synaptotoxic, soluble Ab oligomers, engulf synapses in the absence of plaque aggregates; deletion of CR3 blocks this process. Finally, inhibiting C1q, C3, or CR3 activity rescues synaptic loss and dysfunction.
Our data suggest a local activation of a developmental pruning pathway (5, 6) as a key mechanism underlying oAb-induced synapse loss in preplaque AD brain. C1q is aberrantly increased by diffusible oAb in a region-specific manner and deposits onto synapses, triggering the activation of downstream classical complement pathway and phagocytic microglia. Blocking Ab production in J20 mice significantly ameliorated C1q deposition in the hippocampus, and genetic or antibody-mediated inhibition of complement blocks oAb from inducing microglial synaptic engulfment, synapse loss, and LTP inhibition. These complementary findings have direct therapeutic relevance.
We propose a model in which C1q and oAb operate in a common pathway to activate the complement cascade and drive synapse elimination by microglia through CR3 ( fig. S12 ). This could occur in multiple ways: Soluble oAb associates with synaptic membranes and other synaptic markers (4, 26) ; thus, oAb bound to synapses may anchor C1q directly. Alternatively, oAb binding to synapses may weaken the synapse (4) and expose a C1q receptor. Although specific receptors for C1q at synapses are not yet known, we have shown that C1q binds synapses in vulnerable regions undergoing synapse loss (5, 27) . It is also plausible that oAb and C1q may work indirectly to mediate synapse loss through cytokines such as transforming growth factor-b (7), through microglial or astrocytic activation, or through other mechanisms, including major histocompatibility complex class I (MHCI)-PirB, another immune pathway critical for synapse elimination in development and AD (28) (29) (30) .
Finally, our studies show that resident microglia in the adult central nervous system phagocytose synapses when challenged by synaptotoxic oAb, implicating microglia as potential cellular mediators of synapse loss. Although microglia and complement activation are prominently involved in plaque maintenance and related periplaque neuropathology, their roles have heretofore been largely regarded as a secondary event related to neuroinflammation (2) . Our studies directly challenge this view and suggest that microglia and immune-related pathways can act as early mediators of synapse loss and dysfunction that occur in AD models before plaques form. Although the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, the work reported here provides new insights into how synapses are lost in AD. It will be important in future studies to examine whether this microglia or the complementdependent pathway also plays a role in plaqueassociated synapse loss or in other synaptopathies, including tauopathies and Huntington's disease. If so, our findings may suggest complement and microglia as potential early therapeutic targets in AD and other neurodegenerative diseases involving synaptic dysfunction and memory decline.
